Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats

Here we show that Doxil® has minimal antitumour activity in the isolated limb perfusion (ILP) setting and its activity was not enhanced by the addition of tumour necrosis factor (TNF). Doxil® accumulation in tumour tissue was low and also not augmented by TNF. In contrast, activity of free conventio...

Descripción completa

Detalles Bibliográficos
Autores principales: ten Hagen, T L M, Hoving, S, Ambagtsheer, G, van Tiel, S T, Eggermont, A M M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409755/
https://www.ncbi.nlm.nih.gov/pubmed/15208623
http://dx.doi.org/10.1038/sj.bjc.6601688
Descripción
Sumario:Here we show that Doxil® has minimal antitumour activity in the isolated limb perfusion (ILP) setting and its activity was not enhanced by the addition of tumour necrosis factor (TNF). Doxil® accumulation in tumour tissue was low and also not augmented by TNF. In contrast, activity of free conventional doxorubicin was enhanced by TNF. We conclude that application of Doxil® in a TNF-based ILP is not a useful alternative to free conventional doxorubicin or melphalan.

Ejemplares similares